- Tango Therapeutics is rapidly advancing its lead program, **TNG462**, an MTA cooperative PRMT5 inhibitor, with key data expected to be released later this year.  **[1819133_tx_379756_1]** 
- The company positions **TNG462** as potentially superior to competitors, notably Bristol Myers Squibb (BMS), due to its cleaner profile, allowing for **1.5 to 2 times harder target inhibition** compared to BMS's dose-limiting off-target toxicities.  **[1819133_tx_379756_2]** 
- Tango plans to disclose data on **TNG462** in **pancreatic cancer** in the **second half of this year** at a company event, aiming to demonstrate its potential for **second-line monotherapy** and future **first-line registration**.  **[1819133_tx_379756_3]** **[1819133_tx_379756_4]** 
- A study combining **TNG462** with RevMed's RAS inhibitors was initiated in **late June of this year**, representing a key strategy for **first-line registration** in pancreatic cancer.  **[1819133_tx_379756_5]** 
- Additionally, Tango recently entered the clinic with **TNG456**, a brain-penetrant PRMT5 inhibitor targeting **glioblastoma**, and anticipates data from its CoREST program (TNGX-260) by the **end of the year**.  **[1819133_tx_379756_6]** **[1819133_tx_379756_7]**

Tango Therapeutics (TNGX)